Induction of Hypoxia in the KHT Sarcoma by Tumour Necrosis Factor and Flavone Acetic Acid

References

• Adams G.E., Barnes D., Loutit J., Cole S., Sheldon P., Stratford I.J., Van denAardweg G.J.M.J., Hopewell J., White R., Kneen G., Nethersall A., Edwards C. Induction of hypoxia in normal and malignant tissues by changing the oxygen affinity of haemoglobin: implications for therapy. International Journal of Radiation Oncology, Biology, Physics 1986; 12: 1299–1302
   PubMed Web of Science ®Google Scholar
• Adams G.E., Stratford I.J., Nethersall A.B.W., White R.D. Induction of severe tumour hypoxia by modifiers of the oxygen affinity of haemoglobin. International Journal of Radiation Oncology, Biology, Physics 1989; 16: 1179–1182
   PubMed Web of Science ®Google Scholar
• Adams G.E., Stratford I.J., Bremner J.C., Cole S., Edwards H.S., Fielden E.M. Nitroheterocyclic compounds as radiation sensitizers and bioreductive drugs. Radiotherapy and Oncology 1990, in press
   Google Scholar
• Barendsen G.W., Broerse J.J. Experimental radiotherapy of a rat rhamdomyo sarcoma with ISMeV membrane and 300 kV X-rays. I. Effects of single exposures. European Journal of Cancer 1969; 5: 373–391
   PubMed Web of Science ®Google Scholar
• Bibby M.C., Double J.A., Loadman P.M., Duke C.V. Reduction of tumour blood flow by flavone acetic acid: a possible component of therapy. Journal of the National Cancer Institute 1989; 81: 216–220
   PubMed Web of Science ®Google Scholar
• Bremner J.C.M., Stratford I.J., Bowler J., Adams G.E. Bioreductive drugs and the selective induction of tumour hypoxia. British Journal of Cancer 1990; 61: 717–721
   PubMed Web of Science ®Google Scholar
• Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumours. Proceedings of the National Academy of Sciences, USA 1975; 72: 3669–3670
   Google Scholar
• Cole S., Stratford I.J., Adams G.E. Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU 1069. International Journal of Radiation Biology 1989; 56: 587–591
   PubMed Web of Science ®Google Scholar
• Courtenay D.V. The Courtney clonogenic assay. Human Tumour Drug Sensitivity Testing in vitro: techniques and clinical applications, P.P. Dendy, B.T. Hill. Academic Press, London 1983; 101–109
   Google Scholar
• Elkind M.M., Swain R.W., Alescio T., Sutton H., Moses W.B. Oxygen, nitrogen, recovery and radiation therapy. Cellular Radiation Biology. Williams & Wilkins, Baltimore 1965; 442–461
   Google Scholar
• Evelhoch J.L., Bissery M.-C., Chabot G.G., Simpson N.E., McCoy C.L., Heilbrun L.K., Corbett T.H. Flavone acetic acid (NSC 347512)-induced modulation of tumour physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Research 1988; 48: 4749–4755
   PubMed Web of Science ®Google Scholar
• Finlay G.J., Smith G.P., Fray L.M., Baguley B.C. Effect of flavone acetic acid (NSC 347512) on Lewis lung carcinoma: evidence for an indirect effect. Journal of the National Cancer Institute 1988; 80: 241–245
   PubMed Web of Science ®Google Scholar
• Hewitt H.B., Wilson C.W. The effect of tissue oxygen tension on the radiosensitivity of leukaemia cells irradiated in situ in the liners of leukaemic mice. British Journal of Cancer 1959; 13: 675–684
   PubMedGoogle Scholar
• Hill R.P., Bush R.S., Young P. The effect of the anaemic fraction of hypoxic cells in an experimental tumour. British Journal of Radiology 1971; 44: 299–304
   PubMed Web of Science ®Google Scholar
• Hill S., Williams K.B., Denekamp J. Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. European Journal of Cancer and Clincial Oncology 1989; 25: 1419–1424
   PubMedGoogle Scholar
• Kallinowski F., Schaefer C., Tyler G., Vaupel P. In vivo targets of human tumour necrosis factor-α: blood flow, oxygen consumption and growth of isotransplanted rat tumours. British Journal of Cancer 1989; 60: 555–560
   PubMed Web of Science ®Google Scholar
• Kallman R.F., Silini G., Van Putten L.M. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumours. Journal of the National Cancer Institute 1967; 39: 539–549
   PubMed Web of Science ®Google Scholar
• Manda T., Shimomura K., Mukumoto S., Kobayashi K., Mizota T., Hirai O., Matsumoto S., Oku T., Nishigaki F., Mori J., Kikuchi H. Recombinant human tumour necrosis factor-α: evidence of an indirect mode of anti-tumour activity. Cancer Research 1987; 47: 3707–3711
   PubMed Web of Science ®Google Scholar
• Murray J.C., Smith K.A., Thurston G. Flavone acetic acid induces a coagulopathy in mice. British Journal of Cancer 1989; 60: 729–733
   PubMed Web of Science ®Google Scholar
• Nawroth P.P., Stern D.M. Modulation of endothelial cell hemostatic properties by tumour necrosis factor. Journal of Experimental Medicine 1986; 163: 7040–7045
   Google Scholar
• Palladino M.A., Shalaby M.R., Kramer S.M., Ferraiolo B.L., Baughman R.A., Deleo A.B., Crase D., Marafino B., Aggarwal B.B., Figari I.S., Liggitt D., Patton J.S. Characterisation of the antitumour activities of human tumour necrosis factor-α and the comparison with other cytokines: induction of tumorspecific immunity. Journal of Immunology 1987; 138: 4023–4032
   PubMed Web of Science ®Google Scholar
• Rauth A.M., Kaufman K. In vivo testing of hypoxic radio-sensitizers using the KHT murine tumour assayed by the lung colony technique. British Journal of Radiology 1975; 48: 209–220
   PubMed Web of Science ®Google Scholar
• Sapirstein L.A. Regional blood flow by fractional distribution of indicators. American Journal of Physiology 1958; 193: 161–168
   PubMed Web of Science ®Google Scholar
• Sato N., Goto T., Haranaka K., Satomi N., Nariuchi H., Mano-Hirano Y., Sawasaki Y. Actions of tumour necrosis factor on cultured vascular endothelial cells, morphologic modulation, growth inhibition and cytotoxicity. Journal of the National Cancer Institute 1986; 76: 1113–1121
   PubMed Web of Science ®Google Scholar
• Sheldon P.W., Hill S.A. Hypoxic cell radiosensitizers and local control by X-rays of a transplanted tumour in mice. British Journal of Cancer 1977; 35: 795–868
   PubMed Web of Science ®Google Scholar
• Shimomura K., Manda T., Mukumoto S., Kobayashi K., Nakano K., Mori J. Recombinant human tumour necrosis factor-α: thrombus formation is a cause of anti-tumour activity. International Journal of Cancer 1988; 41: 243–247
   PubMed Web of Science ®Google Scholar
• Shine N., Palladino M.A., Patton J.S., Diesseroth A., Karczmar G.S., Matson G.B., Weiner M.W. Early metabolic response to tumour necrosis factor in mouse sarcoma L: a phosphorus-31 nuclear magnetic resonance study. Cancer Research 1989; 49: 2123–2127
   PubMedGoogle Scholar
• Siemann D.W., Kochanski K. Combinations of radiation and misonidazole in a murine lung tumour model. Radiation Research 1981; 86: 387–397
   PubMedGoogle Scholar
• Smith G.P., Calveley S.B., Smith M.J., Baguley B.C. Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. European Journal of Cancer and Clinical Oncology 1987; 23: 1209–1211
   PubMedGoogle Scholar
• Stratford I.J., Godden J., Howells N., Embling P., Adams G.E. Manipulation of tumour oxygenation by hydralazine increases the potency of bioreductive radiosensitizers and enhances the effect of melphalan in experimental tumours. Radiation Research, E.M. Fielden, J.F. Fowler, J.H. Hendry, D. Scott. Taylor & Francis, London 1987; 2: 737–742
   Google Scholar
• Stratford I.J., Adams G.E., Godden J., Howells N. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo. International Journal of Radiation Biology 1989; 85: 411–422
   Google Scholar
• Stratford I.J., Adams G.E., Bremner J.C.M., Cole S., Ding L., Edwards H.S., Keohane A., Stephens M.A. The assessment of bioreductive drug toxicity in vitro and in vivo. Selective Activation of Drugs by Redox Processes, G.E. Adams, A. Breccia, E.M. Fielden, P. Wardman. NATO Advanced Research Workshop series, Plenum Press, New York 1990, (In press)
   Google Scholar
• Suit H.D., Shalek R.J. Response of spontaneous mammary carcinoma of the C3H mouse to X-irradiation given under conditions of local tissue anoxia. Journal of the National Cancer Institute 1963; 31: 497–509
   PubMedGoogle Scholar
• Sun J., Brown J.M. The bioreductive cytotoxic drug SR 4233 enhances the antitumour effect of flavone acetic acid. Cancer Resarch 1989; 49: 5664–5670
   PubMedGoogle Scholar
• Thomson J.E., Rauth A.M. An in vitro assay to measure the viability of KHT tumour cells not previously exposed to culture conditions. Radiation Research 1974; 58: 262–276
   PubMedGoogle Scholar
• Van der Weil P.A., Bloksma N., Kuper C.F., Hofhuis F.M., Willers J.M. Macroscopic and microscopic early effects of tumour necrosis factor on murine neth A sarcoma, and relation to curative activity. Journal of Pathology 1989; 157: 65–73
   PubMedGoogle Scholar
• Van Putten L.M., Kallman R.M. Oxygen status of a transplantable tumour during fractionated radiation therapy. Journal of the National Cancer Institute 1968; 40: 441–451
   PubMedGoogle Scholar
• Watanabe N., Niitsu Y., Umeno H., Kuriyama H., Heda H., Yamauchi N., Maeda M., Urushizaki I. Toxic effect of tumour necrosis factor on vasculature in mice. Cancer Research 1988; 48: 2179–2183
   PubMed Web of Science ®Google Scholar
• Zwi L.J., Baguley B.C., Gavin J.B., Wilson W.R. Blood flow failure as a major determinant in the antitumour action of flavone acetic acid. Journal of the National Cancer Institute 1989; 81: 1003–1013
   Google Scholar